Phthalates Exposure in Type 2 Diabetic Patients & Diuretic Therapy

Status Active, not recruiting

Clinical Trial Summary

In this open clinical trial, 30 subjects with inadequately controlled T2D and eligible, as per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive a SGLT-2 inhibitor vs other oral-antidiabetic drugs (OADs) therapy for 3 months. Measures will be performed at baseline, after 2 days, after one month and at the end of the study protocol, as per good clinical practice

Clinical Trial Description

- Total concentrations of MEHP, MEOHP and MEHHP will be quantified, in the laboratories of the Institute of Clinical Physiology, National Research Council, Pisa, in a spot morning urine sample by ultra-HPLC coupled with electrospray ionization/quadrupole time-of-flight mass spectrometry (Agilent UHPLC 1290 infinity coupled to an Agilent 6540 MS-QTOF, Santa Clara, CA) using stable isotope labeled substrates, i.e. MEHP (ring-1,2-13C2, dicarboxyl-13C2), MEHHP, MEHHP 13C4, MEOHP and MEOHP 13C4 that will be purchased from Cambridge Isotope Laboratories (Tewksbury, MA).

- Urinary creatinine concentrations will be measured to adjust urinary concentrations of DEHP metabolite (Beckman Coulter AU400, Brea, CA), thus minimizing the inﬂuence of urine volume.

- Serum and urinary inflammatory markers and adipocytokines will be quantitatively determined using sandwich enzyme-linked immunosorbent assays kits according to the manufacturer's instructions. Optical density will be measured using a microplate reader.

- Serum and urinary markers of oxidative stress will be measured by gold standard techniques. In detail, MDA will be quantified by TBARS reactive substances measured by optical density; GSH-Px by a specific assay kit according to the manufacturer's instruction; SOD activity will be determined using a specific SOD kit; urinary 8-isoprostane concentration will be measured by a specific affinity sorbent. (Cayman Chemical, Ann Harbor, MI, USA) according to the manufacturer's instructions.

- To analyze mitochondrial DNA we will apply a triplex design previously reported to amplify mitochondria loci located within the MinorArc and MajorArc, respectively. To assess nuclear DNA, we will use RNase P Copy Number Reference.

- The phthalates-free diet will be self-administered by the individuals under intervention, following a set of instruction and rules provided by the physicians based on the current literature data. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04242758
Study type	Interventional
Source	University of Pisa
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	June 4, 2019
Completion date	April 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05081037` - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)	N/A
Recruiting	`NCT05544266` - Rare and Atypical Diabetes Network
Recruiting	`NCT04039763` - RT-CGM in Young Adults at Risk of DKA	N/A
Active, not recruiting	`NCT05505994` - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin	Phase 3
Completed	`NCT03623113` - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes	N/A
Completed	`NCT03623139` - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes	N/A
Completed	`NCT03359629` - Spectrophon LTD Glucometry Monitor Accuracy
Recruiting	`NCT03682640` - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes	Phase 2
Completed	`NCT02697305` - Incretin Effects of Branched Chain Amino Acids	N/A
Completed	`NCT01737164` - Effect of Age on Glucose and Lipid Metabolism	N/A
Terminated	`NCT00935766` - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries	Phase 3
Recruiting	`NCT03613688` - Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control	N/A
Completed	`NCT04098549` - The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes	N/A
Terminated	`NCT04031404` - Glucose and Non-Invasive Brain Stimulation	N/A
Active, not recruiting	`NCT03577964` - Development of Pneumonia Due to Alveolar Glucose Levels in Systemic Hyperglycemia
Active, not recruiting	`NCT03232008` - Canderel:Effects on Blood Glucose Concentration and Appetite Scores	N/A
Completed	`NCT04042142` - Glucagon Resistance in Patients With NAFLD	N/A
Active, not recruiting	`NCT05607745` - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study	N/A
Completed	`NCT04004273` - Diabetes, Exercise and Liver Fat (DELIVER)	N/A
Completed	`NCT04082923` - Effect of Meal Texture on Glucose-metabolism and Gut Hormone Response After Bariatric Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy — PURITY

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms